Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 16/20 | 0.67 |
| ▸ | MMP1 | P03956 | 14/20 | 0.67 |
| ▸ | MMP7 | P09237 | 10/20 | 0.67 |
| ▸ | MMP8 | P22894 | 7/20 | 0.67 |
| ▸ | MMP2 | P08253 | 5/20 | 0.67 |
| ▸ | MMP13 | P45452 | 3/20 | 0.59 |
| ▸ | MMP9 | P14780 | 6/20 | 0.56 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.55 |
| ▸ | MMP14 | P50281 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6340059 | 1.00 | MMP3 (0.67) | MMP3MMP1MMP7MMP8MMP2 | |
| SCHEMBL6347493 | 0.90 | MMP3 (0.62) | MMP3MMP1MMP7MMP8MMP2 | |
| SCHEMBL6349007 | 0.90 | MMP3 (0.62) | MMP3MMP1MMP7MMP8MMP2 | |
| SCHEMBL6345861 | 0.90 | MMP3 (0.62) | MMP3MMP1MMP7MMP8MMP2 | |
| SCHEMBL6339513 | 0.89 | MMP3 (0.57) | MMP3MMP1MMP7MMP8MMP2 | |
| SCHEMBL6346377 | 0.85 | MMP3 (0.50) | MMP3MMP1MMP7MMP8MMP2 | |
| SCHEMBL6337761 | 0.83 | MMP3 (0.47) | MMP3MMP1MMP7MMP8MMP2 | |
| SCHEMBL6010103 | 0.80 | MMP8 (1.00) | MMP3MMP1MMP7MMP8MMP2 | |
| SCHEMBL7241789 | 0.79 | MMP3 (0.70) | MMP3MMP1MMP7MMP8MMP2 | |
| SCHEMBL7531694 | 0.77 | MMP1 (0.73) | MMP3MMP1MMP7MMP8MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1596846-A2 | INHIBITORS OF HEPATITIS C VIRUS, COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2005-11-23 | — | — | EP | claimed |
| US-20040229817-A1 | Inhibitors of Hepatitis C virus, compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. | 2004-11-18 | — | — | US | claimed |
| WO-2004073599-A2 | INHIBITORS OF HEPATITIS C VIRUS, COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2004-09-02 | — | — | WO | claimed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | claimed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | claimed |
| US-20040235952-A1 | Inhibitors of severe acute respiratory syndrome (SARS) 3C-like proteinase | AGOURON PHARMACEUTICALS, INC. | 2004-11-25 | — | — | US | disclosed |
| US-20040229817-A1 | Inhibitors of Hepatitis C virus, compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. | 2004-11-18 | — | — | US | disclosed |
| WO-2004093860-A1 | INHIBITORS OF SARS RELATED CORONAVIRUS PROTEINASE | PFIZER INC. (US) | 2004-11-04 | — | — | WO | disclosed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229817-A1 | Inhibitors of Hepatitis C virus, compositions and treatments using the same | TIMP3, MMP2, MMP7 | MMP3 5/4885MMP1 10/4885MMP7 3/4885 |
| US-20040235952-A1 | Inhibitors of severe acute respiratory syndrome (SARS) 3C-like proteinase | ACE, ACE2, PRSS3 | MMP3 35/4885MMP1 433/4885MMP7 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.